Barclays Raises Target on Eli Lilly (LLY) After Strong Tirzepatide Growth

Why It Matters

The upgraded target underscores growing confidence in Lilly’s tirzepatide franchise, a key revenue engine, while the reduced Foundayo outlook signals tighter expectations for that pipeline asset. Investors watch these moves as barometers of the company’s earnings trajectory and risk profile.

Key Takeaways

• Barclays lifts LLY price target to $1,400, maintains Overweight rating
• International Mounjaro sales jump 30% driven by tirzepatide demand
• RBC reaffirms $1,250 target after FDA clears Foundayo liver case
• Foundayo FY2026 forecast cut to $1B, below $1.4B Bloomberg average

Pulse Analysis

Eli Lilly’s recent earnings beat highlighted the escalating importance of its tirzepatide platform, which now powers both Mounjaro and the newer obesity drug Zepbound. International demand surged 30% as clinicians adopt the weekly injection for type‑2 diabetes and weight management, reinforcing Lilly’s position as a leader in the fast‑growing GLP‑1 market. The strong topline momentum helped lift analyst sentiment, prompting Barclays to raise its price objective to $1,400 and keep an Overweight stance, signaling confidence that the growth trend will outpace peers.

Analyst upgrades often translate into short‑term price appreciation, and the new target reflects Barclays’ view that tirzepatide’s pipeline extensions and expanding market share will drive earnings multiple expansion. Conversely, the firm trimmed its FY2026 Foundayo revenue estimate to roughly $1 billion, a downgrade from the $1.4 billion Bloomberg consensus, indicating tighter expectations for that asset’s commercial performance. RBC’s decision to reaffirm a $1,250 target after the FDA cleared a solitary liver‑safety incident further steadies the outlook, suggesting that regulatory risk around Foundayo is largely resolved.

Looking ahead, Lilly’s broader portfolio—spanning oncology, immunology, and neuroscience—offers diversification, but the tirzepatide franchise remains the primary catalyst for near‑term growth. Investors will monitor upcoming FDA decisions on next‑generation GLP‑1 candidates and the company’s ability to sustain international sales momentum amid pricing pressures. The mixed analyst signals—a higher overall target but a lower Foundayo forecast—highlight the nuanced balance between high‑growth opportunities and the inherent uncertainties of drug development in a competitive biotech landscape.